Inside Navion: Employee Voices – Giorgio Vescera
Meet Giorgio Vascera, Navion’s Senior Director of Consulting and Analytics.
Articles
Stay Informed, Stay Ahead: CVS’s Transition from Humira to Biosimilars
Earlier this month, CVS announced a major change to some of their formularies. This includes the removal of Humira, a widely used medication.
Spotlight: Featured on Self-Funded with Spencer Podcast
Brian Shonat, Goodroot’s area vice president of business development, recently joined Spencer Smith on the Self-Funded with Spencer podcast
Levemir Discontinuation: What You Need to Know
Important update regarding a recent development about Novo Nordisk’s announcement to discontinue Levemir.
Beyond Unit Cost: Evaluating Clinical Programs and Capabilities of PBMs
Here are three major factors brokers and employer groups should consider beyond unit cost when choosing a PBM.
Medicaid AMP Cap Removal: Market Changes & Rx Strategies Amidst New Provisions
This article dives deep into these shifts and the subsequent reactions from industry stakeholders.
The Cost Implications of New Weight Loss Treatments for Plan Sponsors
Obesity complications are a huge driver of healthcare costs. Could drugs in the latest generation of medications approved to promote weight loss be a solution? These drugs have high costs as well, so payers looking to find the balance don’t face an easy decision of whether or not to cover them.